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Bacterial  lipopolysaccharide  (LPS)  I  has  among its  broad  spectrum  of  immuno- 
logic activities  the capacity to modulate the induction  of a specific  state of 
tolerance  in mice to the thymus-dependent antigen human IgG (HGG), into  a 
specific  state  of  immunity to HGG  (1).  Mice treated  with LPS shortly  after  the 
injection  of  a tolerogenic  dose of  deaggregated HGG  (DHGG) not only fail  to 
become tolerant  to HGG  (2),  but demonstrate a delayed primary response to 
HGG, and also  respond  anamnestically to  a subsequent  immunogenic challenge 
of  aggregated HGG  (AHGG) (1).  This  phenomenon, which has  been  viewed as  a 
very stringent  test  of  an adjuvant  effect  (3),  was originally  described  by Claman 
(4)  with  bovine gamma globulin  tolerance  in  mice,  and has also  been seen  more 
recently  by Ornellas et al. (5)  with sheep gamma globulin  tolerance  in rats. 
Recent  studies  have  been  directed  toward  precisely  defining  the  cellular  basis 
of this modulatory effect  of LPS on HGG  tolerance. It was found that the ' 
immune response to HGG  which is  seen  as  the result  of  dual treatment of  mice 
with DHGG  and LPS appears to occur in spite  of the normal induction  of 
tolerance  in  both HGG-specific thymocytes (1)  and peripheral  T cells  (6).  These 
observations  suggest that LPS not only  prevents tolerance  induction  in B cells, 
but also  overcomes the normal requirement for HGG-specific T-helper cells. 
Furthermore, a positive  correlation  exists  between the capacity of LPS to 
* This is Publication no.  1,019 from the Department of Immunopathology, Scripps Clinic and 
Research Foundation,  La Jolla, Calif. This work was supported by U. S.  Public Health Service 
grant AI-07007, Atomic Energy Commission contract AT (04-3)-410, The American Cancer Society, 
Inc., grant IM-42E, and grants AI-11092 and AI-05875 from the National Institutes of Health. 
Supported by U. S. Public Health Service Training grant AI-00453. 
§ Supported by Dernham Fellowship (no.  D-202) of the California Division of The American 
Cancer Society, Inc. Present address: Department of Allergy and Clinical Immunology, National 
Jewish Hospital and Research Center, Denver, Colo. 80206. 
II Recipient of U. S. Public Health Service Research Career Award 5-K6-GM-6936. 
¶ Supported  by  a  Leukemia  Society of America Special  Fellowship.  Present  address:  The 
Institute for Cancer Research, Philadelphia, Pa.  19111. 
** Supported by the National Institutes of Health grant AI-11092. 
Abreviations used in this paper: AHGG, aggregated HGG; DHGG, deaggregated HGG; HGG, 
human IgG; LPS, bacterial lipopolysaccharide; PFC, plaque-forming cells. 
THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE- VOLUME  143, 1976  143 144  GENETIC  CONTROL  OF  LIPOPOLYSACCHARIDE  ACTIVITIES 
modulate HGG tolerance in vivo and its ability to induce B-cell mitogenesis in 
vitro. One of the most striking correlations between these two properties of LPS 
is the observation that LPS fails to-inhibit tolerance induction to HGG in the 
C3H/HeJ mouse (7), a unique strain whose B cells are refractory to LPS-induced 
mitogenesis (7-10). The lack of an adjuvant effect of LPS in the C3H/HeJ is not 
due  to  the  inability of this  strain to  respond  to  the  antigen HGG,  since  it 
responds as well as other strains to an immunogenic challenge with AHGG (7). 
This correlation, taken together with the observation that HGG-specific T cells 
are tolerant in animals responding to the combination of DHGG and LPS, led to 
the concept that interference with tolerance induction by LPS results from a 
direct mitogenic effect of LPS on HGG-specific B cells (1, 7). As in the case of its 
mitogenic activity (11-16), the adjuvant effect of LPS may also occur without the 
participation of either T cells or macrophages. 
This view is supported by the studies reported here which analyze the genetic 
control of the adjuvant and mitogenic properties of LPS. The refractory state of 
B cells from the C3H/HeJ to LPS-induced mitogenesis is a condition previously 
reported to be due to a single autosomal dominant gene which is not linked to 
either H-2  or  heavy chain  allotype loci  (9). Results  of a  backcross  linkage 
analysis suggest that this gene may be identical to the one which limits the in 
vivo adjuvant activity of LPS in the C3H/HeJ strain. 
Materials and Methods 
Mice.  C3H/HeJ (H-2 k) mice were obtained from The Jackson Laboratory, Bar Harbor, Maine. 
The  breeding  nucleus  of the  C3H.SW-Ig-P  (CWB/13)  strain  was  obtained  from  Dr.  Leonard 
Herzenberg, Stanford University, Stanford, Calif. C3H.SW-Ig-1 b (H-2 ~) differs in IgG2a immuno- 
globulin allotype from other C3H strains, which are Ig-1 ~. (C3H/HeJ  x CWB) F, and (F,  x  C3H/ 
HeJ) backcross mice were bred at the Salk Institute, San Diego, Calif. 
Antigens.  HGG (provided by the American Red Cross National Fractionation Center with the 
partial support of National Institutes of Health grant 13881[HEM]) was prepared either as the 
immunogen, AHGG, or as the tolerogen, DHGG, by methods described previously (17). 
Lipopolysaccharide.  Escherichia  coli  K235 LPS,  prepared by a  phenol-H20 extraction proce- 
dure (18), was generously supplied by Abbott Laboratories, North Chicago, Ill., through Dr. Floyd 
C. McIntire, School of Dentistry, University of Colorado Medical Center, Denver, Colo. 
Allotype Determination.  Backcross mice were tested for the presence of the Ig-1  b allotype of 
the CWB grandparent by using Ouchterlony double-diffusion testing with a  BALB/c anti-BAB/14 
(Ig-1  a anti-Ig-1  b) antiallotype serum (9). 
H-2 Typing.  The backcross mice were tested for the presence of the H-2 b allele from the CWB 
grandparent by using a modification (9) of the polyvinylpyrrolidone technique (19) with a congenic 
H-2 k anti-H-2 ~ typing serum prepared as previously described (9). 
Mitogenic Responses to LPS.  Spleen cell suspensions were cultured and assayed for mitogenic 
responsiveness to LPS by uptake of [SH]thymidine as detailed elsewhere (9). 
Hemolytic Plaque Assay.  Antibody-forming cells specific to HGG were enumerated using the 
Jerne  plaque  assay  (20)  in which  HGG was covalently coupled  to  goat erythrocytes (Colorado 
Serum Co., Denver,  Colo.) (21).  Indirect plaque-forming cells (PFC) were developed with rabbit 
antimouse T-globulin used at a concentration previously determined to be optimal in the assay. 
Results 
In order to determine whether the in vitro mitogenic and in vivo adjuvant 
properties of LPS are controlled by the same gene, a backcross linkage analysis 
was performed utilizing mice  that  were the  progeny of a  cross  between the 
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C3H/HeJ parent.  These  backcross progeny were subsequently tested  individ- 
ually for their ability to support mitogenic and adjuvant responses to LPS.  In 
addition,  two other genetic markers were also assessed which have previously 
been shown to be involved in controlling immunocompetence in mice, namely, 
H-2  (22) and immunoglobulin  heavy-chain allotype (23-25)  loci.  All mice were 
prebled for determination of the H-2 b type and Ig-1 b allotype characteristic of the 
responder  grandparent  strain,  and  10  days  later  these  mice  were  injected 
intraperitoneally with 2.5 mg of DHGG and 3 h later with 25 fig ofE. coli K235 
LPS.  On day 20,  animals  were then challenged  intravenously with 400 ~g of 
AHGG, and 5 days later, the spleens were removed and single cell suspensions 
prepared.  Separate  aliquots  from individual  spleens were then:  (a)  incubated 
with LPS in vitro in order to assess their mitogenic responsiveness to LPS, and 
(b) assayed for their  content  of indirect  PFC  specific to  HGG.  Two groups  of 
animals,  totaling  24  mice,  were tested  in this  manner.  The  results  shown in 
Table I indicate clearly that LPS interfered with the induction of tolerance to 
HGG, as evidenced by the vigorous PFC responses to AHGG, but only in those 
mice  which  were genetically  capable  of supporting  an  in vitro  mitogenic  re- 
sponse to LPS. The remaining animals (9 out of 24) which were genetic nonre- 
sponders to LPS as a mitogen were also nonresponders to LPS as an adjuvant. 
The fact that these two properties of LPS segregate together strongly suggests 
that they are controlled by the same gene.  In contrast,  these properties segre- 
gated independently from the expression of either H-2 or heavy-chain allotype 
loci, and moreover, were not sex linked (Table I). This finding is consistent with 
earlier work demonstrating that mitogenic responsiveness to LPS in mice is a 
condition that is not genetically linked to any of these loci (9). 
Control  experiments  utilizing  additional  groups of animals  established that 
all backcross mice tested could be readily tolerized when treated with DHGG 
alone, or were equally responsive when immunized with AHGG alone (data not 
shown). Thus, as reported previously (7), adjuvanticity is directly attributable to 
the genetic capability of mice to respond mitogenically to LPS, rather than to 
recognize either the tolerogen or immunogen. 
Discussion 
The present studies represent the synthesis of two avenues of research under- 
taken independently in our laboratories that have been directed toward under- 
standing the basis of two immunologic activities of LPS: on the one hand,  the 
definition of the cellular basis of the adjuvant effect of LPS in vivo, and, on the 
other hand, the genetic basis of the mitogenic effect of LPS in vitro. The genetic 
analysis reported here and elsewhere (9) suggests that the expression of a single, 
autosomal dominant gene controls the capacity of C3H/HeJ mice to respond to 
both the mitogenic and adjuvant activities induced by LPS. The importance of 
this  observation  lies  in  the  fact  that  it  provides  the  strongest  evidence  of a 
positive correlation  between these two LPS properties,  since previous experi- 
ments had revealed this relationship by less direct means.  Thus,  experiments 
relating the immunologic effects of LPS to its chemical structure demonstrated 
that  both  its  mitogenic  and  adjuvant  activities  are  properties  that  could  be 
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TABLE  I 
Genetic Linkage between the Mitogenic and Adjuvant Properties of LPS* 
Mice  Sex  Ig-1  H-2 
Mitogenic re-  HGG  response, in- 
sponse,  direct  PFC/10  e 
CPM/culture (E-C)  spleen cells 
Group 1 
4  ?  --  --  6,200  520 
5  ?  b  b  8,790  540 
6  ?  --  --  10,390  696 
7  ?  b  b  12,510  1,298 
8  ~  b  b  40  0 
11  d  --  --  10,150  65 
12  c~  --  --  23,500  405 
13  ~  --  --  880  0 
14  d  b  b  25,380  410 
16  c~  --  --  30,140  247 
17  cT  b  b  0  1 
18  cT  --  b  13,460  1,000 
Group 2 
1  d  --  b  8,240  544 
2  c~  b  b  280  2 
3  ~  b  b  570  0 
4  ?  --  --  0  0 
5  ~  --  --  16,130  264 
10  ?  --  --  8,660  756 
15  ~  --  b  0  0 
16  ~  b  b  0  0 
17  ~  --  b  14,880  274 
18  ~  --  b  22,890  435 
19  d  --  --  0  0 
21  ~  b  b  24,620  506 
* (C3H/HeJ  x CWB)  FI mice were backcrossed to C3H/HeJ mice and the progeny were initially 
prebled for determination of  Ig-1  b allotype and H-2  ~  type of  the responder grandparent. Ig-1 is 
the allotype locus for IgG2a immunoglobulin. CWB  is  Ig-1  b, C3H is Ig-la;  thus, phenotype b = 
genotype b/a and -- = a/a.  CWB  is  H-2  b,  C3H is  H-2k;  thus, phenotype b = genotype b/k  and  - 
k/k. 10 days after  prebleeding, these mice were injected  intraperitoneally with 2.5  mg of  DHGG 
and 3 h later  intravenously (i.v.)  with 25 pg ofE. coli  K235 LPS. 20 days after  this treatment, 
mice were challenged i.v.  with 400 pg  of  AHGG,  and 5 days later  spleen  cells  were harvested and 
aliquots from individual mice were assayed for indirect PFC specific  to HGG,  and tested for 
rnitogenic  responsiveness to LPS. Mitogenic responses were assayed after  66 h of  incubation of 
cells  with 10 ~g/ml ofE. coli  K235 LPS by a 6 h pulse with [3H]thymidine. Results  are expressed 
as the arithmetic mean of  triplicate  cultures after  subtraction of  background into saline-treated 
controls (E-C). 
lipid A  (13).  Similarly,  studies  of the  effects of chemical  alteration  of LPS  on its 
immunologic  activities  have  shown  that  base  hydrolysis  of LPS,  a  treatment 
that  removes  the  ester-linked  fatty  acids  from  lipid  A  without  affecting  the 
structure  of the  O-antigenic  polysaccharide,  resulted  in a  loss of both  its mito- 
genic  and  adjuvant  effects (7).  Lastly,  a  comparison  of the  immunologic  activi- 
ties of LPS  in different  mouse  strains  revealed  that  the  C3H/HeJ  mouse,  unlike 
other  mouse  strains,  was  refractory  to these  two  properties  of LPS  (7). 
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cellular basis of the adjuvant activity of LPS is restricted to B lymphocytes. The 
cellular  location  of the  mitogenic  defect  in  C3H/HeJ  mice  has  been  shown 
previously to reside exclusively at the level of B lymphocytes, rather than at the 
level of accessory cells. This was demonstrated by the fact that in vitro admix- 
ture of spleen cells obtained from responder and nonresponder mice resulted in 
neither enhancement  nor suppression of the mitogenic response to LPS (refer- 
ence 26 and footnote 2). Since the same gene appears to limit both the mitogenic 
and adjuvant properties of LPS in the C3H/HeJ, an intrinsic defect in B cells is 
most likely also responsible for the  lack of an  adjuvant  effect of LPS in  this 
strain, a conclusion which supports the concept that accessory cells are probably 
not involved in the adjuvant effect of LPS reported here. 
Results obtained from other experimental systems suggest that the enhancing 
effect of LPS on antibody responses may be totally dependent on antigen-specific 
T  cells,  either  because LPS has  a  direct potentiating  effect on T  cells,  or  an 
indirect effect on these cells via LPS-activated macrophages (27-29). It is difficult 
to completely rule out the possibility of such accessory cell involvement in the 
present experiments. For example, it is likely that the single gene that controls 
LPS-induced mitogenic responses in B cells is also expressed in other cell types, 
such as T cells and macrophages.  Although the presumptive expression of this 
gene in these accessory cells appears  to exert no significant  influence on the 
mitogenic activity of LPS on B cells, it may have a  profound influence on the 
adjuvant property of LPS. It is also possible that the gene expressed in B cells 
which regulates  the  mitogenic  response  to LPS is  merely linked  closely to a 
different gene, expressed in accessory cells, which limits the adjuvant response. 
In  this  case,  analysis  of a  larger  number  of mice  may  reveal  recombinants 
between these  two LPS properties.  Nonetheless,  it  should be stressed that  a 
normal complement of antigen-specific T  cells is not necessary for the effect of 
LPS on HGG tolerance, since LPS appears to have no influence on the induction 
of tolerance to HGG in specific T  cells (1, 6). 
The coordinate expression of the mitogenic and adjuvant properties of LPS not 
only suggests that the cellular site of action of LPS as an adjuvant is confined to 
B lymphocytes, but also suggests that its subcellular mode of action may result 
from the delivery of a  signal to antigen-specific B cells which is a  stimulus for 
mitogenesis.  This interpretation  would appear to be most compatible with the 
two signal model of immunity proposed by Bretscher (30) and Watson et al. (31). 
Within this conceptual framework,  the role of a  mitogenic signal  would be to 
divert B cells from the tolerogenic pathway initiated by the interaction of DHGG 
with Ig receptors clonally expressed on specific B cells (signal 1), to the inductive 
pathway as a consequence of the interaction of the lipid A moiety of LPS with a 
LPS "receptor" non-clonally expressed on all B cells (signal  2), perhaps  analo- 
gous to that found on human erythrocytes (32).  Whether the gene which limits 
responsiveness to LPS does so by controlling the interaction  of LPS with this 
receptor, or by regulating an LPS-specific event subsequent to this interaction, 
2 Skidmore, B. J., J. M. Chiller, and W. O. Weigle. 1975. Immunologic properties of bacterial 
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is at present unknown.  If the gene defect in C3H/HeJ mice does control the 
expression of LPS receptors,  it apparently does not quantitatively reduce the 
capacity of cells to bind LPS (26). 
An alternative to the two-signal mechanism has recently been proposed by 
Coutinho and  M511er (33, 34), who suggest that the  only signal required  to 
activate B cells is a  single mitogenic stimulus provided either by activated T 
cells or by the  antigen itself,  in the case  of thymus-dependent and thymus- 
independent antigens, respectively.  Mitogenic stimulation by LPS,  however, 
appears  not to be  sufficient to elicit an HGG response.  That is,  there is  an 
absolute requirement for both DHGG and LPS in this system (1). This synergy 
can be explained within the context of the one signal model only if DHGG is 
required not for the delivery of a  specific antigenic signal, but to facilitate in 
some fashion the delivery of a nonspecific mitogenic signal. This may occur, for 
example, by recruitment of LPS-activated macrophages through the interaction 
of  the Fc region of HGG with the Fc receptor on macrophages (35), which may in 
turn secrete mitogenic factors (36). Such a  mechanism must be considered in 
view of the inductive role ascribed to the macrophage (37). 
It is clear that to reach a  firm conclusion will necessitate a  totally in vitro 
analysis of both tolerance and immunity in this system, so that the individual 
contributions of antigen, LPS, and various cell types can be better assessed. The 
LPS-specific defect in the C3H/HeJ mouse strain should provide a valuable tool 
for such an analysis. 
Summary 
The mechanism was investigated underlying the activity of  bacterial lipopoly- 
saccharide  (LPS)  as  an  adjuvant  of antibody formation  as  assessed  by  its 
capacity to modulate the induction of tolerance in mice to the antigen human 
IgG (HGG) into a state of immunity to HGG. The adjuvant activity of LPS was 
found to be closely correlated with its ability to function as a  B-cell mitogen. 
This  correlation  was  revealed  by  an  analysis of the  genetic  control  of the 
mitogenic and adjuvant properties of LPS utilizing the refractory state inherent 
in the C3H/HeJ mouse strain to these activities of LPS. Thus, mice that were the 
progeny of a  backcross  between the  nonresponder  C3H/HeJ  parent  and  the 
responder (C3H/HeJ x  CWB) F~ hybrid were individually typed for responsive- 
ness to LPS,  as an adjuvant and as a  B-cell mitogen. It was found that LPS 
interfered with tolerance induction to  HGG in  vivo only in those backcross 
progeny whose spleen cells were also capable of  responding mitogenically  to LPS 
in vitro, demonstrating that the adjuvant and B-cell mitogenic properties of LPS 
are genetically linked. In contrast, these properties were observed to segregate 
independently from either H-2  or heavy chain allotype loci, and were not sex 
linked. These results are compatible with the concepts that, in this system, (a) 
the cellular site of action of LPS as an adjuvant is confined to B cells, and (b) the 
subcellular mode of action of LPS as an adjuvant may involve the delivery of a 
"signal" to B cells which is a  stimulus for mitogenesis. 
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